Dermatology

PUNE'S TOP DERMATOLOGIST: Viva Luxe by Dr. Sonnal Chavaan Expands to Baner

.

Dermatology segment in IPM poised for 11- 12% growth amid rising demand

The increasing incidence of skin diseases and the growing awareness about these conditions among the Indian populace have been pivotal in driving the dermatology market's expansion

Eris buys India formulation biz of Biocon Biologics for Rs 1,242 crore

The deal would enable Eris' entry into the Rs 3k cr injectables market, and it would become one of major players in the insulins segment with the acquisition of Biocon Biologic's Basalog and Insugen

Biocon to sell branded formulations biz to Eris Lifesciences for $150 mn

Biocon had earlier sold its dermatology and nephrology branded formulation businesses to Eris for Rs 350 crore in November last year

Glenmark, Pfizer launch Abrocitinib in India for Atopic Dermatitis

The prevalence of atopic dermatitis in India has risen over the past three decades, with approximately 5.9 per cent of adults affected, of which 4.4 per cent suffer from a severe form of the disease

Honasa Consumer's profit rises 93% to Rs 29.4 crore in September quarter

According to the firm's first-ever earnings update since its stock market debut earlier this month, consolidated revenue from operations grew 21 per cent Y-o-Y to Rs 496.1 crore

Eris to buy derma, nephro units of Biocon Biologics for Rs 366 cr

The business includes over 20 mother brands with revenue of Rs 90 crore in FY23 and the current run-rate is around Rs 100 crore

L'Oreal brings first brand of its dermatological beauty division to India

While Itani did not specify a timeline, he indicated that other brands from the division might also be introduced in India in the future

Taro stake buyout to help operate dermatology biz profitably: Sun Pharma

Sun Pharma is looking to fully acquire its Israel-based unit Taro Pharmaceutical Industries in order to integrate the dermatology business with itself and keep it profitable amid increasing competition in the segment, according to Managing Director Dilip Shanghvi. The Mumbai-based drug major has proposed to fully acquire Taro through a reverse triangular merger. The company has issued a letter to the Taro board with a proposal containing a non-binding indication of interest to acquire all of the outstanding ordinary shares for a purchase price of USD 38 per ordinary share in cash. Sun Pharma currently owns around 78 per cent stake in Taro. "My own assessment is that the dermatology business, which is the primary focus for Taro, is a business under constant, increasing competition pressure," Shanghvi said in an analyst call. He further said: "And as a stand-alone company, it will be very difficult for Taro as an independent company to continue to operate that business profitably. S

USFDA puts partial clinical hold on Sun Pharma's dermatological drug

USFDA put a partial clinical hold on its application for an experimental dermatological drug due to the potential of thrombotic events

Eris Lifesciences buys dermatology brands from Dr Reddy's for Rs 275 crore

In January Eris had bought some derma brands from Glenmark Pharma as well

Eris Lifesciences Ltd buys 9 dermatology brands from Dr Reddy's for $33 mn

Eris and Dr. Reddy's did not immediately respond to Reuters' requests seeking the names of the dermatology brands

Expensive deal valuations to hit Torrent Pharma's near-term earnings

Sales trajectory in domestic formulations and resolution of regulatory issues are other triggers

Rise of cosmetic dermatology space gets big pharma looking for buyouts

According to reports, Torrent Pharmaceuticals is set to sign a deal to acquire Curatio Healthcare, a maker of skincare products, for Rs 2100 crore.

Eris acquires Oaknet Healthcare for Rs 650 cr for dermatology foray

With a revenue base of Rs 195 crore in FY22, Oaknet brings a portfolio of leading brands in dermatology and women's health to the Eris stable.

Tedious road to recovery: Covid is also altering people's signatures

Children, too, are experiencing aftereffects such as sleeplessness, fatigue, brain fog

Herpes, hair fall, nail issues: Doctors caution about post-Covid problems

From reactivation of herpes infection to loss of hair, several Covid patients in recovery phase are facing one dermatological complication or another due to lowered immunity, say doctors

Asset monetisation, sales uptick in US key triggers for Glenmark Pharma

The India business is expected to post double digit growth in FY22

Lockdown serves domestic pharma the bitter pill: April growth slips

Lack of fresh prescriptions drags growth in acute therapies

Rs 8,700 cr dermatology market is the new king in the pharma sector

Changing climatic conditions, higher pollution and increasing disposable incomes have contributed to the growth